AUTOLOGOUS PBL
Stage III Melanoma
Lisata Therapeutics, Inc.Cell therapyPhase 3Dormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Stage III Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Allovectin-7® Vical | Phase 3 | BB |
Dendritic Cell-Gp100-Mart-1 Antigen Vaccine | Phase 2 | B |
Humax-Cd20 Medical University of Vienna | Phase 2 | B |
Recombinant Human Hyaluronidase Emory University | Phase 2 | CCC |
Procarbazine National Cancer Institute (NCI) | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
AUTOLOGOUS PBL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →